JP2004508399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508399A5 JP2004508399A5 JP2002526363A JP2002526363A JP2004508399A5 JP 2004508399 A5 JP2004508399 A5 JP 2004508399A5 JP 2002526363 A JP2002526363 A JP 2002526363A JP 2002526363 A JP2002526363 A JP 2002526363A JP 2004508399 A5 JP2004508399 A5 JP 2004508399A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- use according
- salt
- physiologically acceptable
- acceptable derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 238000011282 treatment Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045059A DE10045059A1 (de) | 2000-09-12 | 2000-09-12 | Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen |
| PCT/EP2001/010501 WO2002022111A2 (de) | 2000-09-12 | 2001-09-11 | Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508399A JP2004508399A (ja) | 2004-03-18 |
| JP2004508399A5 true JP2004508399A5 (enExample) | 2008-07-10 |
Family
ID=7655916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002526363A Pending JP2004508399A (ja) | 2000-09-12 | 2001-09-11 | 糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030187058A1 (enExample) |
| EP (1) | EP1317264B1 (enExample) |
| JP (1) | JP2004508399A (enExample) |
| CN (1) | CN1216602C (enExample) |
| AT (1) | ATE271866T1 (enExample) |
| AU (1) | AU2001284057A1 (enExample) |
| DE (2) | DE10045059A1 (enExample) |
| DK (1) | DK1317264T3 (enExample) |
| ES (1) | ES2225593T3 (enExample) |
| WO (1) | WO2002022111A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112113A1 (en) * | 2000-08-16 | 2005-05-26 | Till Jonathan S. | Presbyopia treatment by lens alteration |
| US8647612B2 (en) * | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US7914815B2 (en) * | 2000-08-16 | 2011-03-29 | Encore Health, Llc | Method for delivery of pharmaceuticals for treating or preventing presbyopia |
| US8147816B2 (en) * | 2000-08-16 | 2012-04-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US7935332B2 (en) * | 2000-08-16 | 2011-05-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| US8697109B2 (en) * | 2000-08-16 | 2014-04-15 | Encore Health, Llc | Caged mercaptan and seleno-mercaptan compounds and methods of using them |
| DE602004014716D1 (de) * | 2004-03-06 | 2008-08-14 | Cognis Ip Man Gmbh | Use of unsaturated fatty acids for the reduction of appetite or food intake |
| GB0426264D0 (en) * | 2004-11-30 | 2004-12-29 | Trigen Ltd | Compounds |
| JP4556061B2 (ja) * | 2006-07-27 | 2010-10-06 | ビーエイチエヌ株式会社 | ヒアルロン酸産生増強剤 |
| CN101396357B (zh) * | 2007-09-29 | 2010-12-29 | 中国科学院上海生命科学研究院 | 硫辛酰胺在防治胰岛素抵抗中的用途 |
| US9044439B2 (en) * | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| WO2009111635A2 (en) * | 2008-03-05 | 2009-09-11 | Encore Health, Llc | Dithiol compounds, derivatives, and uses therefor |
| EP3069612A3 (en) | 2009-06-15 | 2016-10-19 | Encore Health, LLC | Dithiol compounds, derivatives, and uses therefor |
| WO2010147962A1 (en) | 2009-06-15 | 2010-12-23 | Encore Health, Llc | Choline esters |
| CN101671331B (zh) * | 2009-09-29 | 2011-06-01 | 寿光富康制药有限公司 | 硫辛酰维格列汀及其制备方法与应用 |
| JP5245061B2 (ja) * | 2010-05-12 | 2013-07-24 | ビーエイチエヌ株式会社 | 経口用老化防止剤及び美容方法 |
| AU2014321711B2 (en) | 2013-09-19 | 2019-11-14 | The Research Foundation For The State University Of New York | Methods and materials for treating diabetes or liver steatosis |
| WO2015050809A1 (en) * | 2013-10-01 | 2015-04-09 | Novozymes A/S | Processes of producing fermentation products |
| CA2941518A1 (en) | 2014-03-03 | 2015-09-11 | Encore Vision, Inc. | Lipoic acid choline ester compositions and methods of use |
| US10639322B2 (en) | 2015-03-27 | 2020-05-05 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
| US5962030A (en) * | 1997-03-07 | 1999-10-05 | Akesis Pharmaceuticals, Inc. | Dietary supplement and method of treatment for diabetic control |
| ES2252874T3 (es) * | 1997-12-12 | 2006-05-16 | Purdue Research Foundation | Utilizacion de acido linoleico conjugado para tratamiento de la diabetes mellitus tipo ii. |
| US6440931B1 (en) * | 1999-02-23 | 2002-08-27 | Natural Corporation | Conjugated linoleic acid in treatment and prophylaxis of diabetes |
| US6288106B1 (en) * | 1999-05-25 | 2001-09-11 | Chronorx, Llc | Processes for the synthesis and use of various α-lipoic acid complexes |
| AU2001234782A1 (en) * | 2000-02-02 | 2001-08-14 | Metagenics, Inc. | Compositions and methods for promoting healthy joints |
-
2000
- 2000-09-12 DE DE10045059A patent/DE10045059A1/de not_active Withdrawn
-
2001
- 2001-09-11 CN CN018155413A patent/CN1216602C/zh not_active Expired - Fee Related
- 2001-09-11 US US10/363,658 patent/US20030187058A1/en not_active Abandoned
- 2001-09-11 AT AT01963002T patent/ATE271866T1/de active
- 2001-09-11 WO PCT/EP2001/010501 patent/WO2002022111A2/de not_active Ceased
- 2001-09-11 EP EP01963002A patent/EP1317264B1/de not_active Expired - Lifetime
- 2001-09-11 JP JP2002526363A patent/JP2004508399A/ja active Pending
- 2001-09-11 DK DK01963002T patent/DK1317264T3/da active
- 2001-09-11 ES ES01963002T patent/ES2225593T3/es not_active Expired - Lifetime
- 2001-09-11 AU AU2001284057A patent/AU2001284057A1/en not_active Abandoned
- 2001-09-11 DE DE50103029T patent/DE50103029D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508399A5 (enExample) | ||
| JP2009537559A5 (enExample) | ||
| KR910004571B1 (ko) | 경구용 당뇨병치료 제제를 제조하는 방법 | |
| DeFronzo et al. | Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes | |
| JP2019515884A5 (enExample) | ||
| JP2004522714A5 (enExample) | ||
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| RU2008151414A (ru) | Соединение для лечения метаболических расстройств | |
| US20240423935A1 (en) | Method of initiating or escalating dofetilide dose and formulations therefor | |
| JP2009528375A5 (enExample) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2009528275A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| JP2006518731A5 (enExample) | ||
| JP2006524252A5 (enExample) | ||
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| JP5837919B2 (ja) | （ｅ）−４−カルボキシスチリル−４−クロロベンジルスルホンの改善された安定な水性製剤 | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| RU2006108572A (ru) | Соединения для лечения метаболических нарушений | |
| EP1049471A1 (en) | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids | |
| WO1996038173A1 (en) | Brain edema inhibitor | |
| KR20060100443A (ko) | 이상지혈증의 예방과 치료, 및 이상지혈증 및(또는) 비만과관련된 질환의 예방과 치료를 위한 약제의 제조에있어서의 피라졸 유도체의 용도 | |
| JP2009539877A5 (enExample) | ||
| WO2010117077A1 (ja) | シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤 | |
| JP2009524686A5 (enExample) |